Deerfield, Ill. - July 17, 2015
Baxter International Inc. announced today it is voluntarily recalling two lots of intravenous (IV) solutions to the hospital/user level due to the potential presence of particulate matter. The particulate matter in each case was determined to be an insect and was identified as a result of a customer complaint. The matter was identified prior to patient administration and there have been no adverse events associated with this issue reported to Baxter.
Injecting a product containing particulate matter, in the absence of in-line filtration, may result in blockage of blood vessels, which can result in stroke, heart attack or damage to other organs such as the kidney or liver. There is also the possibility of allergic reactions, local irritation and inflammation in tissues and organs.
This recall affects the following lots:
|Product Code||Product Description||Lot Number||Expiration Date||NDC|
|2B1301||0.9 % Sodium Chloride Injection, USP, 50 mL VIAFLEX Plastic Container||P319921||12/31/2015||0338-0049-11|
|2B0043||0.9% Sodium Chloride Injection, USP, 100 mL MINI-BAG Plus Container||P327635||12/30/2015||0338-0553-18|
0.9 % Sodium Chloride Injection, USP, 50 mL VIAFLEX Plastic Container is intended for intravenous use as a source of water and electrolytes. 0.9% Sodium Chloride Injection, USP, 100 mL MINI-BAG Plus Container is indicated as a source of water and electrolytes, and may also be used as a diluent for reconstitution of a powdered drug product packaged in a vial with a 20 mm closure.
The lots being recalled were distributed to customers and distributors in the United States between October 7, 2014 and July 14, 2015. Baxter is directing customers not to use product from the recalled lots. Recalled product should be returned to Baxter for credit by contacting Baxter Healthcare Center for Service at 1-888-229-0001, Monday through Friday, between the hours of 7:00 a.m. and 6:00 p.m., Central Time. Unaffected lots of product are available for replacement.
Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to using these drug products.
Adverse reactions or quality problems experienced with the use of these products may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1- 800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178.
This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.
Baxter International Inc. provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile IV solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics; and pharmacy automation, software and services. The company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. Baxter’s 50,000 employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.